Illumina sets out 18-Month NovaSeq X roadmap to boost sequencing performance and scale

Gilead to acquire Arcellx to gain full control of anito-cel

AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL

CStone Pharmaceuticals' sugemalimab granted new indication by UK MHRA

FDA accepts Genentech application for giredestrant combination in ESR1-mutated advanced breast cancer

EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer

IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India

AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study

Liminatus Pharma prices USD4.0m public offering

First Ascent Biomedical opens Functional Precision Medicine cancer lab in Miami

Nucleome Therapeutics names new chief scientific officer

Eli Lilly and Company reports positive Phase 3 LIBRETTO-432 results for Retevmo in early-stage RET fusion-positive NSCLC

Ella immunoassay platform gains CE‑IVD approval in the EU

HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer

Innovent reports first participant dosed in Phase 3 trial of IBI354 for first-line treatment of HER2-positive breast cancer